基质金属蛋白酶-2基因1306 C/T多态性与前列腺癌易感性关联的Meta分析
|
摘要
目的系统评价基质金属蛋白酶-2基因(matrix metalloproteinase 2,MMP2)基因rs243865单核苷酸多态性与前列腺癌易感性的关联。方法检索PubMed、Embase、Medline以及中国知网、万方数据库和中国生物医学文献数据库,查找有关MMP2基因rs243865位点多态性与癌症易感性关联的病例对照研究,检索时限为建库至2018年4月1日。由2名研究者筛选文献、提取数据后,使用纽卡斯尔-渥太华量表(Newcastle-Ottawa scale,NOS)进行文献的质量评价。采用Stata 12.0软件进行Meta分析,通过敏感性分析考察结果的稳定性、亚组分析探讨异质性来源、Begg秩相关法评价发表偏倚。结果共纳入6篇文献,合计3909例研究对象,其中前列腺癌患者1921例,健康对照1988例。Meta分析结果显示,等位基因模型T vs. C(OR=1.105,95%CI:0.994～1.227)、隐性基因模型TT vs. CT+CC(OR=1.014,95%CI:0.781～1.315)和纯合子模型TT vs. CC(OR=1.086,95%CI:0.832～1.418)中,癌症易感性差异无统计学意义;显性基因模型TT+CT vs. CC(OR=1.157,95%CI:1.017～1.317)和杂合子模型TC vs. CC(OR=1.498,95%CI:1.078～2.080)中,癌症易感性差异有统计学意义。结论 MMP2基因rs243865多态性与前列腺癌易感性相关,其中C等位基因可能是保护因素,而T等位基因可能是前列腺癌的易感因素,TC基因型可能为前列腺癌患者的风险基因型。
Objective To evaluate the relationship between matrix metalloproteinase 2(MMP2) rs243865 polymorphism and prostate cancer(PCa) susceptibility.Methods The case-control studies about the correlation between MMP2-1306 C/T polymorphism and PCa susceptibility were retrieved from PubMed,Medline,Embase,CNKI,CBM and Wanfang Data by two researchers.The retrieval time was from their establishment to April 1,2018.After the literature screening and data extraction,the Newcastle-Ottawa Scale(NOS) was used to evaluate the quality of studies.The meta-analysis was conducted using Stata 12.0 software.The stability of results was investigated by sensitivity analysis.The source of heterogeneity was explored by subgroup analysis.The publication bias was evaluated by Begg rank correlation test.Results A total of 6 case-control studies involving 1921 PCa patients and 1988 healthy controls were included.Meta-analysis showed that there was no significant difference in cancer susceptibility between allele model T and C(OR=1.105,95% CI:0.994-1.227),as well as between recessive gene model TT and CT+CC(OR=1.014,95% CI:0.781-1.315) and between homozygous model TT and CC(OR=1.086,95% CI:0.832-1.418).However,the difference was significant between dominant gene model TT+CT and CC(OR=1.157,95% CI:1.017-1.317) and between heterozygote model TC and CC(OR=1.498,95% CI:1.078-2.080).Conclusion MMP2 rs243865 polymorphism was associated with PCa susceptibility.The C-allele may be a protective factor,while T-allele may be susceptible to PCa.TC genotype may be a risk genotype for PCa patients.
Objective To evaluate the relationship between matrix metalloproteinase 2(MMP2) rs243865 polymorphism and prostate cancer(PCa) susceptibility.Methods The case-control studies about the correlation between MMP2-1306 C/T polymorphism and PCa susceptibility were retrieved from PubMed,Medline,Embase,CNKI,CBM and Wanfang Data by two researchers.The retrieval time was from their establishment to April 1,2018.After the literature screening and data extraction,the Newcastle-Ottawa Scale(NOS) was used to evaluate the quality of studies.The meta-analysis was conducted using Stata 12.0 software.The stability of results was investigated by sensitivity analysis.The source of heterogeneity was explored by subgroup analysis.The publication bias was evaluated by Begg rank correlation test.Results A total of 6 case-control studies involving 1921 PCa patients and 1988 healthy controls were included.Meta-analysis showed that there was no significant difference in cancer susceptibility between allele model T and C(OR=1.105,95% CI:0.994-1.227),as well as between recessive gene model TT and CT+CC(OR=1.014,95% CI:0.781-1.315) and between homozygous model TT and CC(OR=1.086,95% CI:0.832-1.418).However,the difference was significant between dominant gene model TT+CT and CC(OR=1.157,95% CI:1.017-1.317) and between heterozygote model TC and CC(OR=1.498,95% CI:1.078-2.080).Conclusion MMP2 rs243865 polymorphism was associated with PCa susceptibility.The C-allele may be a protective factor,while T-allele may be susceptible to PCa.TC genotype may be a risk genotype for PCa patients.
引文
[1] JEMAL A,BRAY F,CENTER M M,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2] VAN LINT P,LIBERT C.Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation[J].J Leukoc Biol,2007,82(6):1375-1381.
[3] NO?L A,JOST M,MAQUOI E.Matrix metalloproteinases at cancer tumor-host interface[J].Semin Cell Dev Biol,2008,19(1):52-60.
[4] NAGASE H,VISSE R,MURPHY G.Structure and function of matrix metalloproteinases and TIMPs[J].Cardiovasc Res,2006,69(3):562-573.
[5] STETLER STEVENSON W G.The tumor microenvironment:regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2[J].Cancer Metastasis Rev,2008,27(1):57-66.
[6] SRIVASTAVA P,LONE T A,KAPOOR R,et al.Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India[J].Arch Med Res,2012,43(2):117-124.
[7] ADABI Z,MOHSEN ZIAEI S A,IMANI M,et al.Genetic polymorphism of MMP2 gene and susceptibility to prostate cancer[J].Arch Med Res,2015,46(7):546-550.
[8] DOS REIS S T,PONTES J,VILLANOVA F E,et al.Genetic polymorphisms of matrix metalloproteinases:susceptibility and prognostic implications for prostate cancer[J].J Urol,2009,181(5):2320-2325.
[9] JACOBS E J,HSING A W,BAIN E B,et al.Polymorphisms in angiogenesis-related genes and prostate cancer[J].Cancer Epidemiol Biomarkers Prev,2008,17(4):972-977.
[10] YAYKA?LI K O,KAYIK?I M A,YAMAK N,et al.Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer[J].Turk J Med Sci,2014,44(5):839-843.
[11] SHAJAREHPOOR SALAVATI L,TAFVIZI F,MANJILI H K.The association between MMP2-1306 C>T(rs243865) polymorphism and risk of prostate cancer[J].Ir J Med Sci,2017,186(1):103-111.
[12] STANG A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J].Eur J Epidemiol,2010,25(9):603-605.
[13] DERSIMONIAN R,LAIRD N.Meta-analysis in clinical trials[J].Control Clin Trials,1986,7(3):177-188.
[14] MANTEL N,HAENSZEL W.Statistical aspects of the analysis of data from retrospective studies of disease[J].J Natl Cancer Inst,1959,22(4):719-748.
[15] HAYASHINO Y,NOGUCHI Y,FUKUI T.Systematic evaluation and comparison of statistical tests for publication bias[J].J Epidemiol,2005,15(6):235-243.
[16] 赵国军,黄俊星.PEDF、CCR7和MMP9在食管癌中的研究进展[J].现代肿瘤医学,2014(8):1951-1954.
[17] ROH J,MUELLEMAN T,TAWFIK O,et al.Perineural growth in head and neck squamous cell carcinoma:a review[J].Oral Oncol,2015,51(1):16-23.
[18] TRUDEL D,FRADET Y,MEYER F,et al.Significance of MMP-2 expression in prostate cancer:an immunohistochemical study[J].Cancer Res,2003,63(23):8511-8515.
[19] 黄强,周梁.基于免疫组织化学法分析基质金属蛋白酶2在喉鳞状细胞癌中表达及意义的Meta分析[J].中国眼耳鼻喉科杂志,2018,18(2):105-111.
[20] LI H,QIU Z W,LI F,et al.The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis[J].Oncol Lett,2017,14(5):5865-5870.
[21] LI Y L,SUN B C,ZHAO X L,et al.MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer[J].J Cell Mol Med,2017,21(12):3741-3751.
[22] DENG R U,MO F B,CHANG B E,et al.Glucose-derived AGEs enhance human gastric cancer metastasis through RAGE/ERK/Sp1/MMP2 cascade[J].Oncotarget,2017,8(61):104216-104226.
[23] CHAN O T,FURUYA H,PAGANO I,et al.Association of MMP-2,RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients[J].Oncotarget,2017,8(59):99707-99721.
[24] LIANG R,YAN X X,LIN Y,et al.Functional polymorphisms of the cyclooxygenase-2 gene and prognosis of hepatocellular carcinoma-a cohort study in Chinese people[J].Genet Mol Res,2016,15(2).doi:10.4238/gmr.15028093.
[25] TAO L,LI Z,LIN L,et al.MMP1,2,3,7,and 9 gene polymorphisms and urinary cancer risk:a meta-analysis[J].Genet Test Mol Biomarkers,2015,19(10):548-555.
[26] PRICE S J,GREAVES D R,WATKINS H.Identification of novel,functional genetic variants in the human matrix metalloproteinase-2 gene:role of Sp1 in allele-specific transcriptional regulation[J].J Biol Chem,2001,276(10):7549-7558.
[27] QI F,LIU X,WU H,et al.Long noncoding AGAP2-AS1 is activated by SP1 and promotes cell proliferation and invasion in gastric cancer[J].J Hematol Oncol,2017,10(1):48.
[28] YADAV L,PURI N,RASTOGI V,et al.Matrix metalloproteinases and cancer-roles in threat and therapy[J].Asian Pac J Cancer Prev,2014,15(3):1085-1091.
[29] HAQUE S,AKHTER N,LOHANI M,et al.Matrix metalloproteinase-2 -1306 C>T gene polymorphism is associated with reduced risk of cancer:a meta-analysis[J].Asian Pac J Cancer Prev,2015,16(3):889-896.
[30] JU W,KIM J W,PARK N H,et al.Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer:does ethnicity matter?[J].J Obstet Gynaecol Res,2007,33(2):155-160.
[31] SHIN Y J,KIM J H.The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells[J].PLoS One,2012,7(1):e30393.
[2] VAN LINT P,LIBERT C.Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation[J].J Leukoc Biol,2007,82(6):1375-1381.
[3] NO?L A,JOST M,MAQUOI E.Matrix metalloproteinases at cancer tumor-host interface[J].Semin Cell Dev Biol,2008,19(1):52-60.
[4] NAGASE H,VISSE R,MURPHY G.Structure and function of matrix metalloproteinases and TIMPs[J].Cardiovasc Res,2006,69(3):562-573.
[5] STETLER STEVENSON W G.The tumor microenvironment:regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2[J].Cancer Metastasis Rev,2008,27(1):57-66.
[6] SRIVASTAVA P,LONE T A,KAPOOR R,et al.Association of promoter polymorphisms in MMP2 and TIMP2 with prostate cancer susceptibility in North India[J].Arch Med Res,2012,43(2):117-124.
[7] ADABI Z,MOHSEN ZIAEI S A,IMANI M,et al.Genetic polymorphism of MMP2 gene and susceptibility to prostate cancer[J].Arch Med Res,2015,46(7):546-550.
[8] DOS REIS S T,PONTES J,VILLANOVA F E,et al.Genetic polymorphisms of matrix metalloproteinases:susceptibility and prognostic implications for prostate cancer[J].J Urol,2009,181(5):2320-2325.
[9] JACOBS E J,HSING A W,BAIN E B,et al.Polymorphisms in angiogenesis-related genes and prostate cancer[J].Cancer Epidemiol Biomarkers Prev,2008,17(4):972-977.
[10] YAYKA?LI K O,KAYIK?I M A,YAMAK N,et al.Polymorphisms in MMP-2 and TIMP-2 in Turkish patients with prostate cancer[J].Turk J Med Sci,2014,44(5):839-843.
[11] SHAJAREHPOOR SALAVATI L,TAFVIZI F,MANJILI H K.The association between MMP2-1306 C>T(rs243865) polymorphism and risk of prostate cancer[J].Ir J Med Sci,2017,186(1):103-111.
[12] STANG A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J].Eur J Epidemiol,2010,25(9):603-605.
[13] DERSIMONIAN R,LAIRD N.Meta-analysis in clinical trials[J].Control Clin Trials,1986,7(3):177-188.
[14] MANTEL N,HAENSZEL W.Statistical aspects of the analysis of data from retrospective studies of disease[J].J Natl Cancer Inst,1959,22(4):719-748.
[15] HAYASHINO Y,NOGUCHI Y,FUKUI T.Systematic evaluation and comparison of statistical tests for publication bias[J].J Epidemiol,2005,15(6):235-243.
[16] 赵国军,黄俊星.PEDF、CCR7和MMP9在食管癌中的研究进展[J].现代肿瘤医学,2014(8):1951-1954.
[17] ROH J,MUELLEMAN T,TAWFIK O,et al.Perineural growth in head and neck squamous cell carcinoma:a review[J].Oral Oncol,2015,51(1):16-23.
[18] TRUDEL D,FRADET Y,MEYER F,et al.Significance of MMP-2 expression in prostate cancer:an immunohistochemical study[J].Cancer Res,2003,63(23):8511-8515.
[19] 黄强,周梁.基于免疫组织化学法分析基质金属蛋白酶2在喉鳞状细胞癌中表达及意义的Meta分析[J].中国眼耳鼻喉科杂志,2018,18(2):105-111.
[20] LI H,QIU Z W,LI F,et al.The relationship between MMP-2 and MMP-9 expression levels with breast cancer incidence and prognosis[J].Oncol Lett,2017,14(5):5865-5870.
[21] LI Y L,SUN B C,ZHAO X L,et al.MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer[J].J Cell Mol Med,2017,21(12):3741-3751.
[22] DENG R U,MO F B,CHANG B E,et al.Glucose-derived AGEs enhance human gastric cancer metastasis through RAGE/ERK/Sp1/MMP2 cascade[J].Oncotarget,2017,8(61):104216-104226.
[23] CHAN O T,FURUYA H,PAGANO I,et al.Association of MMP-2,RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients[J].Oncotarget,2017,8(59):99707-99721.
[24] LIANG R,YAN X X,LIN Y,et al.Functional polymorphisms of the cyclooxygenase-2 gene and prognosis of hepatocellular carcinoma-a cohort study in Chinese people[J].Genet Mol Res,2016,15(2).doi:10.4238/gmr.15028093.
[25] TAO L,LI Z,LIN L,et al.MMP1,2,3,7,and 9 gene polymorphisms and urinary cancer risk:a meta-analysis[J].Genet Test Mol Biomarkers,2015,19(10):548-555.
[26] PRICE S J,GREAVES D R,WATKINS H.Identification of novel,functional genetic variants in the human matrix metalloproteinase-2 gene:role of Sp1 in allele-specific transcriptional regulation[J].J Biol Chem,2001,276(10):7549-7558.
[27] QI F,LIU X,WU H,et al.Long noncoding AGAP2-AS1 is activated by SP1 and promotes cell proliferation and invasion in gastric cancer[J].J Hematol Oncol,2017,10(1):48.
[28] YADAV L,PURI N,RASTOGI V,et al.Matrix metalloproteinases and cancer-roles in threat and therapy[J].Asian Pac J Cancer Prev,2014,15(3):1085-1091.
[29] HAQUE S,AKHTER N,LOHANI M,et al.Matrix metalloproteinase-2 -1306 C>T gene polymorphism is associated with reduced risk of cancer:a meta-analysis[J].Asian Pac J Cancer Prev,2015,16(3):889-896.
[30] JU W,KIM J W,PARK N H,et al.Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer:does ethnicity matter?[J].J Obstet Gynaecol Res,2007,33(2):155-160.
[31] SHIN Y J,KIM J H.The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells[J].PLoS One,2012,7(1):e30393.